MCS conducted media relations for MannKind Corporation at the American Diabetes Association’s 69th Scientific Sessions in June 2009, where Phase III data was being presented for MannKind’s lead investigational product, AFRESA® – a novel, ultra-rapid-acting insulin for patients with diabetes.

MCS’ challenge was to seize the spotlight from other significant ADA news, including major, controversial clinical trials, in an effort to help build awareness of AFRESA within the diabetes community. To ensure that MannKind was one of the meeting’s top newsmakers, MCS maximized the opportunity afforded by the 11 AFRESA abstracts that were accepted for ADA. Highlighting AFRESA’s novel attributes, MCS developed press materials and conducted media relations to secure eight interviews for MannKind executives and positive coverage in dozens of top mainstream, trade and social media outlets, including CNBC, Review of Endocrinology and the blog Diabetes Mine.

This entry was posted on Tuesday, August 25th, 2009 at 8:28 pm and is filed under Client News. You can follow any responses to this entry through the RSS 2.0 feed. Responses are currently closed, but you can trackback from your own site.